Alan Packard

Mr. Alan Packard

Boston Children's Hospital
+1

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2018 in Chemical Reviews
Verified
Journal Article
Closed access
EBEszter Boros
Eszter Boros
APAlan Packard
Alan Packard

17 June 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
NDNiels Dammes
Niels Dammes
MGMeir Goldsmith
Meir Goldsmith
SRSrinivas Ramishetti
Srinivas Ramishetti
JDJason L. J. Dearling
Jason L. J. Dearling
NVNuphar Veiga
Nuphar Veiga
Dan PeerDan Peer
Dan Peer

30 October 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SVStephan D. Voss
Stephan D. Voss
SSSuzanne V. Smith
Suzanne V. Smith
NDNadine DiBartolo
Nadine DiBartolo
LMLacey J. McIntosh
Lacey J. McIntosh
ECErika M. Cyr
Erika M. Cyr
APAlan Packard
Alan Packard
The advancement of positron emission tomography (PET) depends on the development of new radiotracers that will complement 18 F-FDG. Copper-64 ( 64 Cu) is a promising PET radionuclide, particularly for antibody-targeted imaging, but the high in vivo lability of conventional chelates has limited its clinical application. The objective of this work was to evaluate the novel chelating agent SarAr (1- N -(4-aminobenzyl)-3, 6,10,13,16,19-hexaazabicyclo[6.6.6] eicosane-1,8-diamine) for use in developing a new class of tumor-specific 64 Cu radiopharmaceuticals for imaging neuroblastoma and melanoma. The anti-GD2 monoclonal antibody (mAb) 14.G2a, and its chimeric derivative, ch14.18, target disialogangliosides that are overexpressed on neuroblastoma and melanoma. Both mAbs were conjugated to SarAr using carbodiimide coupling. Radiolabeling with 64 Cu resulted in >95% of the 64 Cu being chelated by the immunoconjugate. Specific activities of at least 10 μCi/μg (1 Ci = 37 GBq) were routinely achieved, and no additional purification was required after 64 Cu labeling. Solid-phase radioimmunoassays and intact cell-binding assays confirmed retention of bioactivity. Biodistribution studies in athymic nude mice bearing s.c. neuroblastoma (IMR-6, NMB-7) and melanoma (M21) xenografts showed that 15–20% of the injected dose per gram accumulated in the tumor at 24 hours after injection, and only 5–10% of the injected dose accumulated in the liver, a lower value than typically seen with other chelators. Uptake by a GD2-negative tumor xenograft was significantly lower (<5% injected dose per gram). MicroPET imaging confirmed significant uptake of the tracer in GD-2-positive tumors, with minimal uptake in GD-2-negative tumors and nontarget tissues such as liver. The 64 Cu-SarAr-mAb system described here is potentially applicable to 64 Cu-PET imaging with a broad range of antibody or peptide-based imaging agents.

14 September 2020 in Nature Methods
Verified
Journal Article
Closed access
PDF file
AWAndrew W. Woodham
Andrew W. Woodham
SZStad H. Zeigler
Stad H. Zeigler
EZElla L. Zeyang
Ella L. Zeyang
SKStephen C. Kolifrath
Stephen C. Kolifrath
RCRoss W. Cheloha
Ross W. Cheloha
HPHidde L. Ploegh
Hidde L. Ploegh

1 January 2010 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
THTobias K. Heinrich
Tobias K. Heinrich
VGVijay Gottumukkala
Vijay Gottumukkala
ESErin Snay
Erin Snay
PDPatricia Dunning
Patricia Dunning
FFFrederic H. Fahey
Frederic H. Fahey
APAlan Packard
Alan Packard

14 June 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on 99%, P < 0.05). These results support the utility of GD2 imaging with PET to measure GD2 expression in osteosarcoma and thus maximize the clinical impact of anti-GD2 immunotherapy. Significance: In situ assessment of all GD2-positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunotherapy patient selection and enable noninvasive probing of correlations between target expression and therapeutic response.